Commentary

Managing osteoporosis: Challenges and strategies

E. Michael Lewiecki, MD
Cleveland Clinic Journal of Medicine August 2009, 76 (8) 457-466; DOI: https://doi.org/10.3949/ccjm.76a.09019

ABSTRACT

Many patients at high risk of fracture are not being identified and treated, and many of those who start treatment do not take it correctly or long enough to lower their risk. This paper is a review of unmet needs in the management of osteoporosis and strategies to improve clinical outcomes.

Footnotes

  • ↵* Dr. Lewiecki has disclosed that he has received grant or research support from the Amgen, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, Procter & Gamble, Roche, sanofi aventis, and Wyeth companies; has received honoraria for serving on scientific advisory boards of the Amgen, Eli Lilly, Novartis, Roche/GlaxoSmithKline, Upsher-Smith, and Wyeth companies; has received honoraria for teaching and speaking from the Eli Lilly, Novartis, and Roche/GlaxoSmithKline companies; and owns stock in the General Electric, Procter & Gamble, and Teva companies.

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section